Publication: Prevalence of and risk factors for lipodystrophy among HIVinfected patients receiving combined antiretroviral treatment in the Asia-pacific region: Results from the TREAT asia HIV observational database (TAHOD)
Issued Date
2011-07-11
Resource Type
ISSN
13484540
09188959
09188959
Other identifier(s)
2-s2.0-79959944286
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Endocrine Journal. Vol.58, No.6 (2011), 475-484
Suggested Citation
Sang Hoon Han, Jialun Zhou, Suneeta Saghayam, Sasheela Vanar, Nittaya Phanuphak, Yi Ming A. Chen, Thira Sirisanthana, Somnuek Sungkanuparph, Christopher K.C. Lee, Sanjay Pujari, Patrick C.K. Li, Shinichi Oka, Vonthanak Saphonn, Fujie Zhang, Tuti Parwati Merati, Matthew G. Law, Jun Yong Choi Prevalence of and risk factors for lipodystrophy among HIVinfected patients receiving combined antiretroviral treatment in the Asia-pacific region: Results from the TREAT asia HIV observational database (TAHOD). Endocrine Journal. Vol.58, No.6 (2011), 475-484. doi:10.1507/endocrj.K10E-407 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/11513
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Prevalence of and risk factors for lipodystrophy among HIVinfected patients receiving combined antiretroviral treatment in the Asia-pacific region: Results from the TREAT asia HIV observational database (TAHOD)
Other Contributor(s)
Yonsei University College of Medicine
Kirby Institute
YR Gaitonde Centre for AIDS Research and Education
University of Malaya
Thai Red Cross AIDS Research Centre
National Yang-Ming University Taiwan
Research Institute for Health Sciences
Mahidol University
Hospital Sungai Buloh
Institute of Infectious Diseases
Queen Elizabeth Hospital Hong Kong
National Center for Global Health and Medicine
National Center for HIV/AIDS
Beijing Ditan Hospital
Universitas Udayana
Kirby Institute
YR Gaitonde Centre for AIDS Research and Education
University of Malaya
Thai Red Cross AIDS Research Centre
National Yang-Ming University Taiwan
Research Institute for Health Sciences
Mahidol University
Hospital Sungai Buloh
Institute of Infectious Diseases
Queen Elizabeth Hospital Hong Kong
National Center for Global Health and Medicine
National Center for HIV/AIDS
Beijing Ditan Hospital
Universitas Udayana
Abstract
The prevalence of and risk factors for lipodystrophy (LD) among patients receiving combined antiretroviral treatment (cART) in the Asia-Pacific region are largely unknown. LD diagnosis was based on the adverse event definition from the US NIH Division of AIDS (2004 version), and only cases with a severity grade of ≥ 3 were included. TAHOD patients who had recently commenced cART with ≥ 3 drugs after 1996 from sites which had ever reported LD were included in the analysis. Covariates for the forward multivariate logistic regression model included demographic variables, CDC disease classification, baseline CD4 and viral load, hepatitis B/C virus co-infection, and regimen and duration of cART. LD was diagnosed in 217 (10.5%) of 2072 patients. The median duration of cART was 3.8 (interquartile range, 2.2-5.3) years (stavudine, 2.0 (1.0-3.5) years; zidovudine, 1.8 (0.6-3.9) years; and protease inhibitors (PI), 2.6 (1.3-4.5) years). In the multivariate model, factors independently associated with LD included use of stavudine (≤ 2 years vs. no experience: OR 25.46, p < 0.001, > 2 years vs. no experience: OR 14.92, p < 0.001), use of PI ( > 2.6 years vs. no experience: OR 0.26, p < 0.001), and total duration of cART ( > vs. ≤ 3.8 years: OR 4.84, p < 0.001). The use of stavudine was strongly associated with LD in our cohort. Stavudine-sparing cART strategies are warranted to prevent the occurrence of LD in the Asia-Pacific region. ©The Japan Endocrine Society.